Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motomi Mori

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Open Access Bioinformatics|October 25, 2011
Balancing false discovery and false negative rates in selection of differentially expressed genes in microarraysByung S Park, Motomi Mori
Statistical Methods in Medical Research|March 31, 2012
A new statistical decision rule for single-arm phase II oncology trialsYiyi Chen, Zunqiu Chen, Motomi Mori
Pediatric Blood & Cancer|December 14, 2011
Personalized cancer care: opportunities and challenges in pediatric neuro-oncologyLara E Davis, Motomi Mori, Charles Keller
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?Ellen Sidransky, Gregory M Pastores, Motomi Mori
Journal of Hospital Medicine|August 19, 2007
Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgeryThomas W Barrett, Motomi Mori, David De Boer
Carcinogenesis|April 19, 2002
Gene expression profiling of initiated epidermal cells with benign or malignant tumor fatesZhiping Wang, Yuangang Liu, Motomi Mori, et al.
Blood Advances|December 10, 2019
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trialsTaylor Bucy, John M Zoscak, Motomi Mori, et al.
Oncotarget|December 17, 2019
A way forward for cancer prevention therapy: personalized risk assessmentZhenzhen Zhang, Jeffrey Bien, Motomi Mori, et al.
Journal of Hospital Medicine|April 16, 2010
Impact of combination medical therapy on mortality in vascular surgery patientsThomas W Barrett, Kathleen Newton, Caroline Koudelka, et al.
Cancer|May 15, 2013
Agent Orange as a risk factor for high-grade prostate cancerNathan Ansbaugh, Jackilen Shannon, Motomi Mori, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Open Access Bioinformatics|October 25, 2011
Balancing false discovery and false negative rates in selection of differentially expressed genes in microarraysByung S Park, Motomi Mori
Statistical Methods in Medical Research|March 31, 2012
A new statistical decision rule for single-arm phase II oncology trialsYiyi Chen, Zunqiu Chen, Motomi Mori
Pediatric Blood & Cancer|December 14, 2011
Personalized cancer care: opportunities and challenges in pediatric neuro-oncologyLara E Davis, Motomi Mori, Charles Keller
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 7, 2009
Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?Ellen Sidransky, Gregory M Pastores, Motomi Mori
Journal of Hospital Medicine|August 19, 2007
Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgeryThomas W Barrett, Motomi Mori, David De Boer
Carcinogenesis|April 19, 2002
Gene expression profiling of initiated epidermal cells with benign or malignant tumor fatesZhiping Wang, Yuangang Liu, Motomi Mori, et al.
Blood Advances|December 10, 2019
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trialsTaylor Bucy, John M Zoscak, Motomi Mori, et al.
Oncotarget|December 17, 2019
A way forward for cancer prevention therapy: personalized risk assessmentZhenzhen Zhang, Jeffrey Bien, Motomi Mori, et al.
Journal of Hospital Medicine|April 16, 2010
Impact of combination medical therapy on mortality in vascular surgery patientsThomas W Barrett, Kathleen Newton, Caroline Koudelka, et al.
Cancer|May 15, 2013
Agent Orange as a risk factor for high-grade prostate cancerNathan Ansbaugh, Jackilen Shannon, Motomi Mori, et al.
Pageof 11